Ozempic Face: What It Is and How to Prevent It

“Ozempic face” is an informal term for facial volume loss that can happen during faster weight loss on GLP-1 treatment. It is not a separate diagnosis, and it is more about the pace and amount of weight change than about one brand name alone.

What Exactly Is Ozempic Face?

The term “Ozempic face” was popularized by dermatologist Dr. Paul Jarrod Frank in media interviews to describe the gaunt, aged facial appearance he observed in patients experiencing rapid weight loss on semaglutide medications. It is not unique to Ozempic's active ingredient — the same facial changes can occur with any significant weight loss, whether from Wegovy, Mounjaro, bariatric surgery, or even intensive diet and exercise programs.

The face contains distinct fat pads — in the cheeks (malar fat pads), temples, and around the eyes — that provide youthful volume and contour. When you lose weight rapidly, these fat pads shrink along with body fat, leading to a hollow, deflated appearance. According to the American Society of Plastic Surgeons (ASPS), the rate of facial procedures increased by 4.3% from 2023 to 2024, with facial plastic surgeons reporting a 50% rise in fat grafting procedures — a trend linked in part to patients addressing GLP-1 related facial volume loss.

What Causes Ozempic Face?

Three overlapping biological mechanisms drive the facial changes associated with rapid weight loss on GLP-1 medications. Understanding each one helps explain why some patients are more affected than others.

Facial fat loss. GLP-1 receptor agonists promote systemic fat reduction. The body does not selectively preserve facial fat while losing abdominal or visceral fat. In the STEP 1 trial, semaglutide 2.4 mg reduced total fat mass by 19.3% and visceral fat mass by 27.4% from baseline over 68 weeks. The face, with its relatively thin layer of subcutaneous fat, shows these reductions prominently — particularly in the temples, cheeks, and under-eye areas.

Lean tissue loss. Not all weight lost on GLP-1 medications is fat. An exploratory analysis of the STEP 1 trial found that lean body mass decreased by approximately 9.7% with semaglutide, and some research suggests that up to 25–40% of total weight lost can come from lean tissue if protein intake is not adequate. The facial muscles that support the overlying skin also lose volume, contributing to sagging.

Reduced skin elasticity. Rapid weight loss lowers collagen and elastin production in the skin. Collagen provides structural support, while elastin allows the skin to snap back after stretching. When weight is lost quickly, the skin may not have enough time to contract and remodel, resulting in loose, drooping skin — especially in areas like the jawline and neck where skin is thinner.

Who Is Most at Risk for Ozempic Face?

Not everyone who takes a GLP-1 medication will develop noticeable facial changes. Several factors increase the likelihood and severity of Ozempic face.

Age. Patients over 40 have naturally lower collagen and elastin levels, meaning the skin is less able to bounce back after volume loss. The ASPS reports that people ages 35 to 55 comprised 32% of facelift clients in 2024, up from 26% in prior years — a shift partly attributed to GLP-1 related facial aging.

Amount and speed of weight loss. Losing more than 1–2 pounds per week increases the chance of noticeable facial volume loss. Patients who lose 15% or more of their body weight are more likely to experience visible changes.

Starting body composition. Individuals with less facial fat to begin with, or those who are naturally lean in the face, tend to notice hollowing sooner. Conversely, patients with more starting facial volume may tolerate moderate weight loss without significant facial changes.

Genetics and skin type. Sun-damaged skin, lighter skin tones with less structural melanin, and a family history of facial aging all increase susceptibility. Smoking history also plays a role, as it damages collagen fibers over time.

How Can You Help Prevent Ozempic Face?

While some degree of facial volume loss may be unavoidable with significant weight loss, several evidence-based strategies can help minimize its severity. Talk to your healthcare provider before making changes to your treatment plan.

Prioritize protein intake. Eating enough protein is the single most important dietary strategy for preserving lean tissue during weight loss on GLP-1 medications. Current guidance suggests aiming for 1.2 to 1.6 grams of protein per kilogram of body weight daily, which is significantly higher than the standard recommendation of 0.8 g/kg. For a 180-pound (82 kg) person, that translates to roughly 98–131 grams of protein per day. For more details, see our guide on how GLP-1 medications work and their effects on appetite and nutrient absorption.

Add resistance training. Strength training 2–3 times per week helps preserve muscle mass throughout the body, including the facial muscles. A combination of adequate protein intake and regular resistance exercise has been shown to significantly reduce lean tissue loss during GLP-1 therapy.

Aim for gradual weight loss. Losing weight at a rate of 1–2 pounds per week gives the skin more time to adapt and contract. Discuss your dose titration timeline with your provider — for example, the standard Ozempic dose escalation schedule is designed in part to moderate the rate of weight change.

Stay hydrated and protect your skin. Adequate water intake supports skin elasticity, and daily broad-spectrum sunscreen (SPF 30 or higher) protects against UV-induced collagen breakdown. Topical retinoids, which stimulate collagen synthesis, may also help maintain skin firmness — ask your dermatologist if they are appropriate for you.

Track your progress.Monitoring your weight loss rate, protein intake, and overall well-being can help you and your provider catch rapid changes early. Glone's tracking features let you log your weight alongside your medication side effects so you can spot trends and adjust your plan proactively.

What Treatment Options Exist for Ozempic Face?

If facial volume loss has already occurred, several cosmetic and dermatological treatments can help restore a more youthful appearance. These should be discussed with a board-certified dermatologist or plastic surgeon.

Hyaluronic acid (HA) dermal fillers. Injectable fillers such as Juvederm and Restylane can immediately restore volume to the cheeks, temples, and under-eye hollows. Results typically last 6–18 months depending on the product and treatment area. HA fillers are reversible, which makes them a lower-risk starting point.

Biostimulatory fillers.Products like Sculptra (poly-L-lactic acid) and Radiesse (calcium hydroxylapatite) work differently from HA fillers — they stimulate your body's own collagen production over several months. Results develop gradually across 2–3 treatment sessions and can last up to 2 years. These are often recommended for more diffuse or significant volume loss.

Skin tightening procedures. Technologies such as radiofrequency microneedling (Morpheus8), ultrasound therapy (Ultherapy), and bipolar radiofrequency devices stimulate collagen remodeling to tighten loose skin. A 2025 clinical study on bipolar radiofrequency treatment for Ozempic face reported that the majority of patients achieved satisfaction scores of 8 or higher out of 10, with results remaining stable over the follow-up period.

Fat grafting. For patients seeking a longer-lasting solution, autologous fat transfer involves harvesting fat from another area of the body (such as the abdomen or thighs) and injecting it into the face. The ASPS reports that facial fat grafting procedures rose by 50% in 2024, reflecting growing demand from GLP-1 medication users.

Is Ozempic Face Permanent?

The facial changes associated with rapid weight loss are not necessarily permanent, but they do not always fully resolve on their own. If weight stabilizes and no additional fat is lost, the skin may gradually tighten over 6–12 months as collagen remodels. However, significant facial fat loss — especially in patients over 40 — may not fully reverse without cosmetic intervention.

It is also worth noting that if a patient stops taking their GLP-1 medication and regains weight, some facial volume may return. However, this is not a recommended strategy for addressing facial changes, as weight cycling carries its own health risks. For more on what happens after discontinuation, see our article on how GLP-1 medications work.

Does Ozempic Face Happen With All GLP-1 Medications?

Yes. Despite the name, Ozempic face is not specific to Ozempic. Any GLP-1 receptor agonist that produces significant weight loss can lead to the same facial changes. The table below compares the average weight loss in key clinical trials, which correlates with the likelihood of facial volume loss.

Because higher weight loss generally means greater facial volume change, medications that produce more significant weight loss — such as Mounjaro and Zepbound at their maximum doses — may carry a higher risk of noticeable facial changes. However, individual results vary widely based on the risk factors discussed above.

When Should You Talk to Your Doctor About Ozempic Face?

If you are concerned about facial changes while taking a GLP-1 medication, bring it up with your healthcare provider. They may recommend adjusting your dose escalation schedule to slow the rate of weight loss, refer you to a registered dietitian to optimize your protein intake, or suggest a consultation with a dermatologist for skin-supportive treatments.

It is important to weigh the cosmetic concerns against the significant metabolic benefits of GLP-1 therapy. These medications have demonstrated reductions in cardiovascular events, blood sugar levels, and overall mortality risk in clinical trials. Your provider can help you find a balance between achieving your health goals and managing facial changes.

Tracking your medication, weight, and side effects in one place can make these conversations with your provider more productive. Glone helps you log all of this information so you can share clear trends at your appointments.

Sources

• Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity” (STEP 1) — nejm.org
• Kosiborod MN, et al. Body composition analysis in the STEP 1 trial — pmc.ncbi.nlm.nih.gov
• “Ozempic Face” in Plastic Surgery: A Systematic Review — pmc.ncbi.nlm.nih.gov
• Emergence of “Ozempic Face”: Addressing Unintended Consequences of Rapid Weight Loss — pmc.ncbi.nlm.nih.gov
• American Society of Plastic Surgeons — 2024 Plastic Surgery Statistics Report — plasticsurgery.org
• “Ozempic Face”: An Emerging Drug-Related Aesthetic Concern and Treatment with Bipolar Radiofrequency — pmc.ncbi.nlm.nih.gov